| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/27/2008 | EP1959943A1 Orally administered antibiotics for the treatment of hemorrhoids |
| 08/27/2008 | EP1959942A1 Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol |
| 08/27/2008 | EP1959941A1 Neramexane modified release matrix tablet |
| 08/27/2008 | EP1959940A2 Localized delivery of drug combinations |
| 08/27/2008 | EP1959939A1 Use of a3 adenosine receptor agonist in osteoarthritis treatment |
| 08/27/2008 | EP1959938A2 Matrix-controlled transdermal system comprising salts of ace inhibitor dicarboxylic acids |
| 08/27/2008 | EP1959937A1 Transdermal therapeutic system |
| 08/27/2008 | EP1959936A2 Once-daily administration of central nervous system drugs |
| 08/27/2008 | EP1959935A2 Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
| 08/27/2008 | EP1959934A2 Bilayer tablet comprising telmisartan and diuretic |
| 08/27/2008 | EP1959933A1 Process for the perparation of lyophilized piperacilline sodium with improved stability after reconstitution |
| 08/27/2008 | EP1959931A2 Compositions and methods for dermally treating pain |
| 08/27/2008 | EP1959929A2 Compositions and methods for treating dermatological conditions |
| 08/27/2008 | EP1959927A1 Composition in the form of a spray containing a corticoid and an oil phase |
| 08/27/2008 | EP1959926A1 Formulation comprising a drug of low water solubility and method of use thereof |
| 08/27/2008 | EP1959925A2 Controlled release microparticles |
| 08/27/2008 | EP1959921A2 Foam wafer containing a polyvinyl alcohol-polyethyleneglycol-graft copolymer |
| 08/27/2008 | EP1959915A1 Mixtures comprising anthranilic acid amides and antidandruff agents as cosmetic and pharmaceutical compositions for alleviating itching |
| 08/27/2008 | EP1959764A2 Nutritional supplement containing long-chain polyunsaturated fatty acids |
| 08/27/2008 | EP1959763A1 High-potency sweetener composition with phytosterol and compositions sweetened therewith |
| 08/27/2008 | EP1959738A2 Certain chemical entities, compositions and methods |
| 08/27/2008 | EP1959737A2 Chemical compounds |
| 08/27/2008 | EP1905763A4 N-acylic aminoacid derivatives. method for the production thereof, pharmacological composition and the use in the form of anti-allergic, anti-inflammatory and hypolipidemic agents |
| 08/27/2008 | EP1858881B1 Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1'-binaphthalene-2, 2'diol |
| 08/27/2008 | EP1807095A4 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome |
| 08/27/2008 | EP1799636B1 Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives |
| 08/27/2008 | EP1765776B1 Novel tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs) |
| 08/27/2008 | EP1765337B1 Combination of tenofovir, ritonavir and tmc114 |
| 08/27/2008 | EP1751144B1 Constrained himbacine analogs as thrombin receptor antagonists |
| 08/27/2008 | EP1748797B1 Use of biguanides and method of sterilisation |
| 08/27/2008 | EP1716145B1 Dihydrotetrabenazines and pharmaceutical compositions containing them |
| 08/27/2008 | EP1709066B1 Inclusion complexes of perindopril |
| 08/27/2008 | EP1708996B1 Fused heteroyral derivatives for use as p38 kinase inhibitors |
| 08/27/2008 | EP1697318B1 Prolinylarylacetamides |
| 08/27/2008 | EP1694659B1 Thiadiazoles as cxc- and cc- chemokine receptor ligands |
| 08/27/2008 | EP1660484B1 Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists |
| 08/27/2008 | EP1654255B1 Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors |
| 08/27/2008 | EP1651661B1 Process for the preparation of finasteride form i |
| 08/27/2008 | EP1644368B1 Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators |
| 08/27/2008 | EP1626974B1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 08/27/2008 | EP1625114B1 Piperidine derivatives for the the treatment of chemokine or H1 mediated diseases |
| 08/27/2008 | EP1622856A4 Heat activated tertiary amine urethane catalysts |
| 08/27/2008 | EP1622569A4 Aza spiro alkane derivatives as inhibitors of metallproteases |
| 08/27/2008 | EP1606275B1 Opioid receptor antagonists |
| 08/27/2008 | EP1601668B1 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| 08/27/2008 | EP1596810B1 Use of banana extract for the treatment of inflammatory bowel disease |
| 08/27/2008 | EP1594886B1 Antitumoral d-homoestra-1, 3, 5 (10)-trien-3-yl 2-substituted sulfamates |
| 08/27/2008 | EP1587507A4 A method of treatment or prophylaxis of symptoms of herpes viral infection |
| 08/27/2008 | EP1581474B1 Chiral arylketones in the treatement of neutrophil-dependent inflammatory deseases |
| 08/27/2008 | EP1531814B1 Sustained-release tablet composition of pramipexole |
| 08/27/2008 | EP1526850B1 Use of vitamin C for the treatment of Charcot-Marie-Tooth disease |
| 08/27/2008 | EP1474146B1 Phenylpyrimidine amines as ige inhibitors |
| 08/27/2008 | EP1467997B8 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group |
| 08/27/2008 | EP1455781B1 Use of anastrozole for the treatment of post-menopausal women having early breast cancer |
| 08/27/2008 | EP1450804B1 Pharmaceutical formulations comprising an immune response modifier |
| 08/27/2008 | EP1440156B1 Antigens and vectors for vaccination |
| 08/27/2008 | EP1411916B1 Methods and materials for the treatment of testosterone deficiency in men |
| 08/27/2008 | EP1408981B1 Methods for preventing antipsychotic-induced weight gain |
| 08/27/2008 | EP1406895B1 Lactone formulations and method of use |
| 08/27/2008 | EP1392284B1 Methods of treating hyperlipidemia |
| 08/27/2008 | EP1384726B1 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |
| 08/27/2008 | EP1368325B1 New asymmetric process for the preparation of diarylmethylpiperazines derivatives and novel asymmetric diarylmetylamines as intermediates |
| 08/27/2008 | EP1359909B1 Triptolide prodrugs for anti-cancer therapy |
| 08/27/2008 | EP1349858B1 Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof |
| 08/27/2008 | EP1337560B1 Truncated cd200 |
| 08/27/2008 | EP1337262B1 Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative |
| 08/27/2008 | EP1313714B1 Valsartan salts |
| 08/27/2008 | EP1307188B1 Ajulemic acid for the treatment of cancer |
| 08/27/2008 | EP1273295B1 Composition comprising ozonized oils and/or other natural and/or synthetic ozonized products and use thereof in pharmaceutical, cosmetic, dietetic or food supplement compositions, in the human and veterinary fields |
| 08/27/2008 | EP1210078B1 Improved topical medicaments and methods for photodynamic treatment of disease |
| 08/27/2008 | EP1115418B1 Diagnosis of cancers associated with viral infections using aglycoprotein 10B |
| 08/27/2008 | EP1089994B9 Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same |
| 08/27/2008 | EP1007555B1 Tropoelastin derivatives |
| 08/27/2008 | EP0952832B1 Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors |
| 08/27/2008 | EP0949931B1 Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| 08/27/2008 | EP0649429B1 Heteroatomic oligonucleoside linkages |
| 08/27/2008 | CN101253502A Drug, drug guidance system, magnetic detection system, and drug design method |
| 08/27/2008 | CN101253270A Prophylactic/ameliorating agent for menopausal disorder and functional beverage/food |
| 08/27/2008 | CN101253192A Antitumor agent |
| 08/27/2008 | CN101253190A Bate-L-N4-hydroxycytosine deoxynucleosides and their use as pharmaceutical agents in the prophylaxis or therapy of viral diseases |
| 08/27/2008 | CN101253180A 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as CXC-chemokine receptor ligands |
| 08/27/2008 | CN101253178A Use of fused imidazole derivatives to mediate CCR3 related conditions |
| 08/27/2008 | CN101253177A Bicyclic heterocycles as HIV integrase inhibitors |
| 08/27/2008 | CN101253176A Novel crystalline form of a pyridazino [4, 5-b] indole derivative |
| 08/27/2008 | CN101253173A Hydroxy substituted 1H-imidazopyridines and methods |
| 08/27/2008 | CN101253172A N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| 08/27/2008 | CN101253168A Substituted benzimidazoles as kinase inhibitors |
| 08/27/2008 | CN101253167A Substituted imidazole compounds as KSP inhibitors |
| 08/27/2008 | CN101253166A Sulfonamide compound |
| 08/27/2008 | CN101253165A Di-substituted oxadiazoles as CXC-chemokine receptor ligands |
| 08/27/2008 | CN101253164A Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists |
| 08/27/2008 | CN101253159A Diaminopyrimidines as P2X3 and P2X2/3 modulators |
| 08/27/2008 | CN101253155A 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 |
| 08/27/2008 | CN101253154A Novel ansamycin derivatives |
| 08/27/2008 | CN101253153A 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d] azepines as 5-HT2c receptor agonists |
| 08/27/2008 | CN101253151A GPCR agonists |
| 08/27/2008 | CN101252952A Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid |
| 08/27/2008 | CN101252940A Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases |
| 08/27/2008 | CN101252939A Steroidal glycoside compounds as core 2N-glcnac-t inhibitors |
| 08/27/2008 | CN101252938A Combined preparation of a thiazide diuretic and a loop diuretic |